IRCT20090609002017N32 IRCT 2018-08-11 Vice chancellor for research , Tabriz University of Medical Sciences, Nutrition Research Center Assessment of Oleoylethanolamide supplementation in prevention and treatment of non-alcoholic fatty liver disease Assessment of oleoylethanolamide supplementation on the expression of SIRT1, AMPK, PGC-1α, PPAR-γ, CEBP-α, CEBP- β, IL-6, and IL-10 genes, serum IL-6, IL-10, hs-CRP, IL-1β, TNF-α, TAC, GSH-Px, SOD, catalase, MDA, ox-LDL, and NRG-4 levels, and body composition in obese patients with non-alcoholic fatty liver disease (NAFLD) 2019-04-21 anticipated 60 Complete https://irct.ir/trial/31612 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Samples are assigned to intervention and control groups using simple random design, Blinding description: In this study, the main investigator and patients will be blind (oleoylethanolamide or placebo) . The person responsible for preparing the supplement sachets  (who is completely unrelated to the study) will be asked to assign a three  digit code to each of the two powders (oleoylethanolamid and placebo), and keep the codes for himself until the end of the study and data analyses. N/A Non-alcoholic fatty liver disease. Intervention 1: Intervention group: daily 2 capsules including 125 mg oleoylethanolamide. Intervention 2: Control group: daily 2 capsules including 125 mg placebo. Yes - There is a plan to make this available What will be shared: Data collected for the primary outcomes will be shared. When: access starting 12 months after publication To whom: The data will only be available for people working in academic institutions. Conditions: The data of the present study will only be accessible by other researchers,  for conducting Meta-analysis. Where to obtain: The researchers (student and her supervisor) How to obtain: Request a document via email Comments: